(CercleFinance.com) – MedinCell jumps 10% after signing a licensing agreement with the Medicines Patent Pool (MPP), a United Nations-backed public health organization whose mission is to improve access to essential drugs in poor countries.
The agreement concerns an injectable formulation of ivermectin with a duration of action of three months, using MedinCell’s BEPO technology, against the transmission of malaria. It aims to ensure that the product will be widely distributed if it proves to be effective and safe.
Still endemic in 91 countries representing half of the world’s population, malaria caused 627,000 deaths in 2020. Children under five are the most vulnerable, accounting for 80% of deaths.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
